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Abstract
Aging increases the risk to develop several neurodegenerative diseases, although the underlying mechanisms are poorly
understood. Inactivation of the Polycomb group gene Bmi1 in mice results in growth retardation, cerebellar degeneration,
and development of a premature aging-like phenotype. This progeroid phenotype is characterized by formation of lens
cataracts, apoptosis of cortical neurons, and increase of reactive oxygen species (ROS) concentrations, owing to p53-
mediated repression of antioxidant response (AOR) genes. Herein we report that Bmi1 expression progressively declines in
the neurons of aging mouse and human brains. In old brains, p53 accumulates at the promoter of AOR genes, correlating
with a repressed chromatin state, down-regulation of AOR genes, and increased oxidative damages to lipids and DNA.
Comparative gene expression analysis further revealed that aging brains display an up-regulation of the senescence-
associated genes IL-6, p19
Arf and p16
Ink4a, along with the pro-apoptotic gene Noxa, as seen in Bmi1-null mice. Increasing
Bmi1 expression in cortical neurons conferred robust protection against DNA damage-induced cell death or mitochondrial
poisoning, and resulted in suppression of ROS through activation of AOR genes. These observations unveil that Bmi1
genetic deficiency recapitulates aspects of physiological brain aging and that Bmi1 over-expression is a potential
therapeutic modality against neurodegeneration.
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Introduction
Aging is the prime risk factor for the development of several
neurodegenerative diseases. Although the reason for this is
unknown, it is possible that specific neuronal genes having
protective roles in the aging brain are down-regulated due to
increased mutational rate and/or defective DNA repair at their
promoter [1]. Moreover, long lived neuronal cells are more likely
to accumulate mutations in their genomic DNA than most other
cell types with age, leading to impaired cellular functions [2,3].
This phenomenon may be explain in part due to the inability of
post-mitotic cells to replicate their DNA, a process that is tightly
coupled to DNA damage checkpoint and DNA repair [4,5,6].
Moreover, neurons possess a high metabolic activity and consume
large amount of O2, and thus are exposed to higher levels of
oxidative stress compared to other tissues [3,6].
Mitochondria are not only cellular organelles required for
aerobic respiration but are also the main source of intracellular
reactive oxygen species (ROS), which are thought to be causal for
most oxidative damage accumulation with age [3,7,8]. The
balance between ROS and antioxidant molecules is critical to
determine the rate of oxidative damage accumulation, and thus
possibly cellular and organism lifespan [9]. The free radical theory
of aging is partially supported by gain- and loss-of-function
experiments showing that antioxidant-encoding genes such as
catalase, Cu/Zn superoxide dismutase (Sod1) and Mn superoxide
dismutase (Sod2) are critical determinants of lifespan
[10,11,12,13]. Thus, reduced antioxidant response (AOR) genes
expression in the aging brain could displace the oxidative balance
and may instigate accelerated aging and age-related neurodegen-
erative diseases.
Polycomb group proteins form large multimeric complexes that
silence specific target genes by modifying chromatin organization
[14]. The Polycomb group protein Bmi1 is a component of the
Polycomb Repressive Complex 1 (PRC1), which promotes
chromatin compaction and gene repression through its histone
H2A E3-mono-ubiquitin ligase activity [15,16,17]. Bmi1
2/2 mice
present axial skeleton defects, reduced post-natal growth and
lifespan, along with progressive cerebellar degeneration [18,19].
Yet, we previously reported that Bmi1
2/2 mice develop a
progeroid phenotype in the central nervous system characterized
by lens cataracts, cortical neurons apoptosis, p53 activation and
oxidative damage accumulation [20]. Bmi1
2/2 neurons are also
hypersensitive to mitochondrial toxins, to DNA-damaging agents
and to intracellular b-amyloid peptides, and display elevated ROS
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Notably, most of Bmi1 functions on the oxidative metabolism of
neurons can be explained by p53-mediated repression of AOR
genes expression [20,21].
In this study, we investigated the possible molecular links
between physiological brain aging and Bmi1 genetic deficiency,
and analyzed Bmi1 neuroprotective potential. We show that in the
aging brain, where Bmi1 expression declines in the neurons, there
is an up-regulation of inflammatory and senescence markers,
accumulation of p53 to AOR gene promoters, reduced expression
of AOR genes and elevated oxidative damage to neurons, in a
pattern that is similar to that of Bmi1
2/2 mice. Increasing Bmi1
expression in cortical neurons was highly neuroprotective against
inhibition of the mitochondria respiratory chain or the DNA
topoisomerase I, and resulted in activation of antioxidant defenses
and in suppression of ROS levels. This work suggests that
modulation of Bmi1 expression in the aging or disease-affected
brain could provide robust neuroprotective activity.
Materials and Methods
Ethical statement
Animals were maintained in our facilities and used in
accordance with and after approval by the Animal Care
Committee of the Maisonneuve-Rosemont Hospital Research
Center (Approval ID #2008-27 and #2009-42). Paraffin-embed-
ded archival brains were obtained from the department of
pathology of the Maisonneuve-Rosemont Hospital. Post-mortem
human eyes were provided by the Eye’s Bank of our institution
and used with permission of Maisonneuve-Rosemont Hospital
ethical committee.
Adenovirus/plasmid constructs
Human BMI1 (2436 to +2175; GeneBank Accession #
NM_005180) cDNA was cloned by PCR using human retina
cDNA, and inserted into the DUAL-IRESGFP plasmid for
adenovirus production (Vector Biolabs). BMI1 cDNA was also
cloned into the CMV-GFP:EF1a lentiviral vector.
Neuronal cultures
Embryonic day 18.5 cortical neurons were cultured as described
previously [20]. Cortices were dissected in oxygenated HBSS.
Following meninges removal, cortices were cut to ,1m m
3 pieces,
and incubated at 37uC for 15 min in 2 ml TrypleEx solution
(Invitrogen). Afterwards, enzymatic solution was discarded, and
cortex pieces dissociated in HBSS with a 1 ml tip (10 times up and
down). After dissociation, cells were plated at 1.5610
5 cells/well
on poly-L-lysine-coated 6-well plates or 8-well cultures slides (BD
Biosciences). Cells were maintained in normal medium composed
of Neurobasal-A Medium (Invitrogen), Glutamax-I (Gibco),
gentamycin (50 mg/ml; Gibco), B27 supplement (Gibco), NGF
(50 ng/ml; Invitrogen) and BDNF (0.5 ng/ml; Invitrogen).
Neurons were nucleofected with plasmid DNA using the Mouse
Neuron Nucleofector Kit according to manufacturer’s instructions
(Amaxa Biosystems).
Chromatin immunoprecipitation (ChIP)
ChIP was performed using the ChIP Assay kit (Upstate). Briefly,
1–1.5610
6 fixed cells were sonicated for 10 sec at 30% amplitude
to shear the chromatin (Branson Digital Sonifier 450, Crystal
Electronics, On. Canada). Sonicated materials were immunopre-
cipitated using 2 mg mouse anti-p53 (DO-1), rabbit anti-
H3Me2Lys9, rabbit anti-H3Me2Lys27 (Cell signaling), rabbit
anti-Acetyl-H4, and anti-mouse IgG (Upstate) antibodies. Pro-
moter fragments were amplified using primers to xCT, Sod2 and b
major chain as specified in Information S1.
Animals
Bmi1
+/2 mice (in C57Bl/6J background) were a gift from M.
Van Lohuizen (The Netherlands Cancer Institute, Amsterdam).
Wild type C57Bl/6J inbred mice were purchased from Charles
River Canada.
Immunohistochemical analysis, quantitative real-time
PCR, Western blot, measurement of ROS and lipid
peroxidation levels
Technical details are provided in Information S1 [22].
Statistical analysis
Statistical differences were analyzed using Student’s t-test for
unpaired samples. An analysis of variance (ANOVA) followed by
the Dunnett test was used for multiple comparisons with one
control group. In all cases, the criterion for significance (P value)
was set as mentioned in the figures.
Results
Bmi1 is down-regulated in mouse cortical neurons
during aging
To evaluate Bmi1 expression in neurons during aging, we
analyzed sections of cerebral cortices from young (2 months) and
old (21–26 months) mice using immunohistochemistry. We
observed that Bmi1 expression decreased significantly in old
NeuN
+ cortical neurons, but not in GFAP
+ astrocytes (Figure 1A).
In old neurons, Bmi1 labeling was not uniform, with some neurons
expressing Bmi1 at moderate levels, while others showing nearly
undetectable levels (Figure 1A). Immunolabeling was not present
in cortical sections from Bmi1
2/2 mice, confirming the specificity
of the antibody (Figure S1). Referring to a previous report
proposing that Bmi1 is not down-regulated in the aging mouse
brain [23], we measured Bmi1 levels in a large cohort of young
(n=15) and old (n=15) inbred mice. Using whole cerebral
extracts and quantitative RT-PCR (Q-PCR), we found that Bmi1
mRNA levels decrease by ,60% in old cortices, thus suggesting
reduced Bmi1 transcription (Figure 1B). Interestingly, Bmi1
expression levels were highly variable in the old age population,
with some mice showing only 20% of Bmi1 levels compared to
young mice (Figure 1B). To confirm our observations at the
protein levels, we perform Western blot analysis of whole cortices
from young and old mice, which revealed a ,40% reduction in
Bmi1 levels in old mice (Figure 1C). To address the possibility that
a variation in cell population numbers could underlies the
observed reduction in Bmi1 levels, we counted and compared
the number of NeuN
+ neurons/cortical area or over the total
number of cortical cell nuclei in young and old mice, but found no
difference (Figure 1D).
p16
Ink4a and p19
Arf are the main targets of Bmi1 transcriptional
repressive activity in most of cell types, including cortical neurons
[18,20]. Expression of p16
Ink4a and p19
Arf was increased concom-
itantly with Bmi1 reduction in old brains (Figure 2A). The
similarity between normal brain aging and Bmi1 genetic deficiency
also extended to Noxa, a p53-regulated gene involved in apoptosis,
and IL-6, which is involved in inflammation and inflammatory
senescence (Figure 2A) [24,25]. Infection of cultured Bmi1
2/2
neurons with a dominant negative adenovirus against p53
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those of p16
Ink4a and p19
Arf (Figure S2), which are primary Bmi1
targets [18,20,26]. To further seek for possible gene expression
pattern resemblances between brain aging and Bmi1 genetic
deficiency, we compared the expression of AOR genes in cortices
of both young and old mice, and of post-natal day (P) 25 WT and
Bmi1
2/2 mice. Notably, several genes involved in ROS scaveng-
ing were down-regulated in old brains, revealing a general
decrease in antioxidant defenses (Figure 2B). Common down-
regulated genes between Bmi1
2/2 brains and old brains were
xCT, NQO1 and Sod2 (Figure 2B). These genes are also down-
regulated in cultured Bmi1
2/2 neurons [20]. To commensurate
the above observations, we compared the accumulation of
oxidative damages between young and old brains, and between
WT and Bmi1
2/2 P25 brains or cultured neurons. Concentrations
of oxidized lipids were increased in old brains (1.4060.05,
P,0.05, n=3) compared to the young samples, similarly as
between Bmi1
2/2 (1.4360.03, P,0.05, n=3) and WT brains or
Bmi1
2/2 (2.5460.12, P,0.01, n=3) and WT e18.5 neurons.
Concomitant with this finding, accumulation of oxidized genomic
DNA bases (8-hydroxydeoxyguanosine) was elevated in neurons of
old and P25 Bmi1
2/2 brains (Figure 2C) [27,28]. In cortical
neurons, 8-oxoguanine lesions were found in both nuclear and
mitochondrial DNA (Figure 2C). This latter finding implies
increased oxidative DNA damages in cortical neurons from old
and P25 Bmi1
2/2 mice owing to reduced antioxidant defenses.
This primary defect may be combined with a reduction in 8-
oxoguanine DNA glycosylase (OGG1) activity or level [29,30,31].
It was previously showed that p53 proteins levels progressively
increase in the aging rat brain [28]. Furthermore, p53 protein can
associate with the promoters of AOR genes such as those encoding
glutathione S-transferase alpha 1 (GSTa1), NAD(P)H quinone
oxidoreductase (NQO1) and xCT. Upon damage, activated p53
can repress the transcription of these genes and interfere with the
antioxidant defense system normally activated by the Nrf2
transcription factor [32]. To test for a possible mechanism of
AOR genes downregulation in the aging brain, we compared
young and aged brains for p53 accumulation at the xCT and Sod2
promoters by ChIP. We found that p53 was enriched at the xCT
promoter and in two distinct Sod2 promoter regions in aged brains
(Figure 2D). Interestingly, this correlated with a repressed
chromatin state, as shown by the accumulation of heterochromatin
marks at these promoters, similarly as found in cultured Bmi1
2/2
neurons (Figure 2D) [20].
Figure 1. Bmi1 is down-regulated in the aging mouse brain. A) Coronal sections from the cerebral cortex were analyzed by IHC using Bmi1
and NeuN (top panels), or Bmi1 and GFAP (lower panels) antibodies. Bmi1 (brown) is highly expressed in NeuN
+ (pink) neurons and its expression
decreases with age, while it remains unchanged in GFAP
+ (Pink) astrocytes. Note that in aged neurons, Bmi1 labeling was not uniform, with some
neurons expressing Bmi1 at moderate levels (blue arrowheads), while others showing nearly undetectable level (red arrowheads). Scale bars; 20 mm.
(B) The relative expression of Bmi1 in cortices from young and old brains was analyzed by Q-PCR. Each point represents a comparison between one
old and one young mouse cortex. The blue line represents the mean, and the red line represents the standard deviation (n=15; **P,1.022E
224).
(C) Young (40–55 days old) and old (21–26 months old) mice brain samples were analyzed by Western blot for Bmi1 expression. Protein loading was
normalized using b-actin and a-tubulin. Data in brackets are levels of Bmi1 and are expressed as Mean 6 s.d. (n=4 brains per group; *P,0.05).
(D) The numbers of neurons (NeuN+ cells) and non-neuronal cells (NeuN- cells) were counted in young and old mice brain slices. (left panel) Data
were presented as absolute neuron number per cortical field. (right panel) Data were expressed as the percentage of neurons versus all cortical cells
(neurons + non-neuronal cells). Results are Mean +/2 s.d. (n=3 brains per age, and counts were made on 4 to 9 slices per brain; P=0.18).
doi:10.1371/journal.pone.0031870.g001
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To test if age-dependent Bmi1 down-regulation was restricted to
mice, we analyzed BMI1 expression in young and old human
brains by immunohistochemistry. We observed that BMI1
expression was reduced in hippocampal neurons of old brains
(Figure 3A). In contrast to the observations found in mice, BMI1 is
not expressed in normal human astrocytes, even in young brains
[20]. We previously reported on Bmi1 expression in post-mitotic
neurons of the mouse retina. Using immunofluorescence, we
analyzed BMI1 expression in the adult human retina. We
observed robust BMI1 immunoreactivity in the nucleus of
photoreceptors and weaker expression in neurons of the inner
nuclear and ganglion cell layers (Figure 3B). The peculiar
expression of BMI1 in some photoreceptors was distinct from
classical polycomb bodies staining (Figure 3B). To quantify for
possible BMI1 down-regulation in the aging human retina, we
performed Western blot analysis using young (4–30 years old),
middle-aged (40 and 50 years old) and old (65–75 years old)
human retinas. BMI1 protein levels were variable from sample to
sample, especially in the young and middle-aged groups, in
agreement with previous studies [1]. Nonetheless, BMI1 levels
were consistently lower in old human retinas (Figure 3C). Linear
regression analysis suggests a stepwise reduction in BMI1 levels,
and where expression between 85–95 years of age could be, on
average, less than 30% of what is found in young individuals.
However, due to samples limitations, BMI1 expression in retinas
older than 75 years could not be tested in this study. Reactive
gliosis in the retina and in the brain is observed in neurodegen-
erative diseases, CNS lesions and during aging and can be
visualize by GFAP immunoreactivity. P16
INK4A represents a
biomarker of tissue aging and is a target of Bmi1 repressive
activity [23,33,34]. Consistently, we observed increased GFAP
and P16
INK4A immunoreactivity in sections of aged human retinas
(Figure 3D), similarly as observed in the retina and the brain of
Bmi1
2/2 mice at P25 [20,35].
Bmi1 over-expression is neuroprotective and activates
antioxidant defenses
To test if increasing Bmi1 expression could protect neurons
from damage-induced cell death, we generated a plasmid
expressing the complete human BMI1 cDNA (Figure 4A). This
expression vector was electroporated in e18.5 WT cortical neurons
that were thereafter exposed or not to neuronal toxins (Figure 4B).
Using immunohistochemistry, neurons viability was determined by
the absence of activated caspase-3 and the maintenance of long
axons and dendrites presenting a rich arborization, similarly as
observed in vehicle-treated neurons. When neurons were exposed
to 5 mM of camptothecin (CA), a DNA topoisomerase I inhibitor
that leads to single-strand DNA breaks formation and p53-
mediated neuronal apoptosis, only ,40% of control-GFP
electroporated neurons were viable after 16 hours
[24,36,37,38,39]. In contrast, ,80% of GFP/BMI1-transfected
neurons remained viable after this time point (Figure 4C and D).
These data revealed that BMI1 is required and sufficient to block
CA-induced apoptosis cell autonomously. To test if BMI1 over-
expression was neuroprotective against a mitochondrial toxin, we
Figure 2. Antioxidant defenses are reduced in the aging mouse brain. (A) The relative expression of senescence-associated genes in cortices
from young and old brains was analyzed by Q-PCR. Results are Mean 6 s.d. (n=3; *P,0.05; **P,0.01). The dashed line represents the basal gene
expressionlevel measuredin young mice. (B) Therelative expression of antioxidantgenes in cortices fromyoung and old brains, and fromP25 Bmi1
2/2
and WT mice was analyzed by Q-PCR. The dashed line represents the basal gene expression level measured in young compared to old and to WT
compared to Bmi1
2/2 mice. Results are Mean 6 s.d. (n=3; *P,0.05; **P,0.01). (C) Coronal sections from the cerebral cortex of young and old mice,
and of P25 WT and Bmi1
2/2 mice were labeled with antibodies against 8-oxo-guanine (8-OG; brown) and GFAP (pink). Note the increase in 8-oxo-
guanine labeling in neurons from old and Bmi1
2/2 mice compared to respective controls. Scale bars; 50 mm. (D) ChIP analysis of young and old
brains revealing accumulation of p53 and heterochromatin marks (histone H3 K27
me2 or H3 k9
me2) at the xCT, Sod1 and Sod2 promoters in old brains.
Antibodies against acetylated histone H4 and IgG were used as control. The b-major promoter region of globin was use as negative control. Results
are Mean 6 s.d. (n=3; *P,0.05).
doi:10.1371/journal.pone.0031870.g002
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succinate dehydrogenase inhibitor that blocks complex II of the
mitochondria respiratory chain [40,41]. 3-NP treatment induced
caspase-3-dependent (apoptosis) and caspase-3-independent (vac-
uolization) neuronal cell death (Figure 4C). At this high
concentration, only ,21% of GFP-electroporated neurons
remained viable after 16 hours. In contrast, ,77% of GFP/
BMI1-transfected neurons remained viable at this concentration,
showing that BMI1 over-expression confers cell autonomous
protection against 3-NP toxicity (Figure 4C and D). We previously
reported that p53 protein levels were increased in Bmi1
2/2
neurons and that the major effects of Bmi1 genetic deficiency were
mediated by p53 pro-apoptotic and pro-oxidant activity. To test
part of the mechanism involved in BMI1 neuroprotective activity,
we over-expressed BMI1 by DNA electroporation in WT and
p53
2/2 neurons treated or not with 5 mM of CA. We observed
that although p53
2/2 neurons were highly resistant to CA
treatment compared to WT neurons, this effect was further
enhanced when BMI1 was over-expressed (Figure 4E).
To address if BMI1 activity correlated with ROS modulation
and induction of AOR genes expression, a BMI1-expressing
adenovirus was used to infect cortical neurons in culture. 48 hours
post-infection, neurons were treated or not with 8 mM of 3-NP
and analyzed 6 hours later for ROS concentrations. We found
that BMI1 over-expression reduced ROS concentrations in
untreated neurons (Figure 5A). This biochemical effect was
reflected by an increase in phase II genes (i.e. xCT, NQO1 and
GST-1a) expression by an order of 3–9 fold and induction of
Sestrin1 and Sod2 by an order of 1.5–2 fold (Figure 5B). Upon 3-
NP exposure, we also observed a reduction in ROS concentrations
in BMI1-overexpressing neurons relative to GFP-infected neurons,
and this was again reflected by activation of antioxidant genes
(Figure 5A and B). We concluded that in gain-of-function
experiments, BMI1 can reduce ROS levels and over-activate
antioxidant defenses. Notably, p53
2/2 neurons infected with the
BMI1-expressing adenovirus or control adenovirus (GFP-only)
showed nearly identical ROS concentrations, and these were
comparable to ROS concentrations found in WT neurons infected
Figure 3. BMI1 is down-regulated in the aging human brain and retina. (A) Immunohistochemistry on human brain (hippocampus) sections
using anti-Bmi1 (brown) and anti-GFAP (pink) antibodies. BMI1 is expressed in neurons, but not in GFAP+ astrocytes, and expression is highly reduced
in old brain neurons. Note the virtual absence of BMI1 labeling in some neurons (red arrowheads). Scale bars; 20 mm. (B) Immunofluorescence analysis
of BMI1 expression in the human retina (23 years old, frozen sections). BMI1 is highly expressed in human photoreceptors (white arrowheads), which
cell body lies in the outer nuclear layer (ONL), while its expression is weaker in neurons of the inner nuclear (INL) and ganglion cell (GCL) layers (red
arrowheads). Scale bars; 20 mm. (C) Human retina samples were analyzed by Western blot for BMI1 expression and protein content was normalized
using b-actin. BMI1 protein levels are reduced in old retinas (65–75 years). Results are Mean 6 s.d. (n=2–5 retinas per group; *P,0.05).
(D) Immunofluorescence analysis of GFAP and P16
INK4A expression in young and old human retinas. Note increased GFAP and P16
INK4A
immunoreactivity in the old retinas. Scale bars; 20 mm.
doi:10.1371/journal.pone.0031870.g003
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results suggest that parts of BMI1 neuroprotective activities may
be p53-independent and not mediated through regulation of ROS
concentrations.
Discussion
Herein, we demonstrated that the Polycomb group gene Bmi1
is down-regulated in the brain and the retina of aged mice and
humans. Moreover, numerous aspects of brain aging, but not all,
are recapitulated in the progeroid phenotype of Bmi1
2/2 mice,
suggesting a model linking Bmi1 deficiency and unregulated p53
activity to reduced antioxidant defenses in the aging brain. On
the other hand, we presented evidences that BMI1 over-
expression is neuroprotective, can activate AOR genes, and can
suppress ROS.
In the central nervous system of mammals, peroxisome
proliferator-activated receptor gamma coactivator-1a (PGC-1a)
has been shown to be a major inducer of the antioxidant defense
system. Consistent with this, dopaminergic neurons from PGC-1a-
null mice are hypersensitive to the mitochondrial complex I
inhibitor MPTP, and PGC-1a over-expression is neuroprotective
against paraquat and H2O2 [42]. Likewise, Nrf2 over-expression
in astrocytes can protect neurons in a non-cell autonomous
manner from 3-NP toxicity, while Sirt1 over-expression can delay
axonal degeneration and counteract neurodegeneration in a
mouse model of Alzheimer disease [40,41,43,44]. However, with
the exception of a modest reduction in Nrf1 mRNA levels, the
Figure 4. BMI1 is highly neuroprotective against topoisomerase I inhibition and mitochondrial poisoning. (A) Empty plasmid vectors
(CMV-GFP) or human BMI1-carrying plasmid (CMV-GFP: BMI1) were transfected in 293FT cells and lysates were analyzed 72 hours later for Bmi1
expression by Western blot. b-actin was used as internal control for normalization of protein loading. Non-transfected cells were used as control (Ctl)
for endogenous Bmi1 expression. (B) Experimental scheme showing the procedure used to electroporate plasmid vectors in primary neuronal
cultures from e18.5 WT mouse embryo cortices. (C) After 7 days in vitro (DIV), electroporated neurons were exposed to CA, 3-NP or their respective
vehicles. 16 hours later, cultures were stained for apoptosis induction (caspase-3 in brown) and expression of GFP (in pink), in order to distinguish
neurons carrying or not the transgene. (D) Cell viability was assessed in cultures photographed in (C) as the percentage of GFP
+/Caspase-3
2 cells
versus total GFP
+ cells. Results are Mean 6 s.d. (n=3; *P,0.05; **P,0.001). (E) After 7 DIV, electroporated WT and p53
2/2 neurons were exposed to
CA or vehicle (DMSO) and analyzed after 16 hours as described in (C). Results are Mean 6 s.d. (n=3; **P,0.001).
doi:10.1371/journal.pone.0031870.g004
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and protein levels in Bmi1
2/2 mice [20]. Hence, the neuropro-
tective effects of BMI1 over-expression against CA and 3-NP
toxicity are unlikely to be mediated through modulation of these
factors. Rather, we propose that most of these effects are mediated
through repression of p53 activity. In support of this 1) AOR genes
expression profile of BMI1-overexpressing neurons is similar to
that of p53-null neurons, and 2) p53 is the central mediator of CA-
induced apoptosis in neurons [20,24,36,37,38,39]. On the other
hand, we also showed that BMI1 over-expression in p53
2/2
neurons confers increased neuronal survival after CA treatment,
but not reduction in ROS concentrations. Our finding suggests
that BMI1 neuroprotective activities are not only mediated via
p53-dependent and ROS-dependent pathways. Although numer-
ous possibilities exist, this could be achieved through BMI1
repression of alternate tumor suppressors and/or improved DNA
damage response and repair [45,46,47]. Notably, the mechanism
by which Bmi1 regulates p53 activity remains elusive, although
repression of the p19
Arf/Mdm2/p53 pathway through direct
transcriptional repression of p19
Arf by Bmi1 remains a possibility.
The contexts of Bmi1 deficiency in mice (which leads to a severe
and early lethal pathology) and of physiological aging are
completely different. Hence, it is most unexpected that Bmi1
down-regulation in neurons during brain physiological aging leads
to a molecular phenotype that resembles Bmi1 genetic deficiency.
The apparent conservation of the Bmi1-p53 antioxidant relation-
ship during physiological aging is thus an important finding that
brings new knowledge on the mechanisms regulating the process
of physiological aging in the central nervous system. Our previous
findings provided a molecular mechanism to explain why Bmi1-
null neurons age prematurely and are hypersensitive to various
stressors [20]. Considering Bmi1 down-regulation in the aging
central nervous system, this may also explain why aged neurons
are more sensitive to various insults. Cellular and DNA damage
produced by mitochondrial ROS have been proposed to be the
causal factor of cellular and organismal aging [1,3,7]. Herein we
observed that p53 accumulates at AOR gene promoters in the
aging mouse brain, correlating with reduced AOR genes
expression. This suggests that deficient BMI1 expression in the
human brain may contribute to reduce antioxidant defenses,
leading to accumulation of oxidative damage and neuronal
dysfunction. Although controversial, neuroinflammation is poten-
tially a driving force of normal brain aging and neurodegenerative
diseases. The cytokine IL-6 is a biomarker of brain aging, and high
levels of IL-6 are found in senescent cells and Alzheimer disease
brains [25,48]. We found that old and Bmi1
2/2 brains expressed
high levels of IL-6, and that this was p53-dependent in cultured
Bmi1
2/2 neurons. These observations suggest that Bmi1 deficien-
cy during aging could amplify p53 activity and thus accelerate the
process of normal brain aging and age-related neurological
diseases in readily susceptible individuals (see proposed model in
Figure 6). Finally, while increased p53 activity in aging neurons
may be in part explained by the loss of Bmi1 expression, the age-
associated mechanism leading to Bmi1 down-regulation remains
to be investigated. Although this mechanism apparently operates
at the transcriptional level, as reported for other genes in the aging
brain [1], age-dependent Bmi1 mRNA degradation through
specific miRNA activity is possible [49]. Also, it cannot be
excluded that activated p53 represses Bmi1 transcription, although
such evidences do not exist yet. At last, Bmi1 protein may be also
preferentially targeted for degradation in aging neurons
[50,51,52]. In old mice, Bmi1 expression declined only in neurons,
not in astrocytes. Notably, only astrocytes have the potential to
generate tumors. These data indicate that down-regulation of the
Bmi1 oncogene in neurons during aging is apparently not a
general response to prevent cancer (at least in mice). Rather, it
may represent an epigenetic change related to normal brain aging
[1]. Taken together, our work suggests that targeted pharmaceu-
tical stimulation of Bmi1 expression in aging neurons could prevent
accumulation of age-associated oxidative damages, protect against
apoptosis and possibly counteract the progression of neurodegen-
erative diseases.
Supporting Information
Figure S1 Coronal sections of WT and Bmi1
2/2 mice
brains were analyzed by IHC using Bmi1 (brown) and
Figure 5. BMI1 over-expression activates AOR genes and
suppresses ROS. (A and B) e18.5 WT neurons were infected with
BMI1-expressing (Adeno-BMI1) or GFP-expressing (Adeno-GFP) adeno-
viruses. 48 hours post-infection, neurons were treated or not with
8 mM of 3-NP and analyzed 6 hours later. (A) ROS levels were measured
with the fluorescent dye DCFDA. Data were normalized to the protein
contents and expressed as fold change relative to levels in Adeno-GFP-
infected cells. Results are Mean 6 s.d. (n=3 independent cultures;
*P,0.05; **P,0.01). (B) relative gene expression was analyzed by Real-
Time PCR. Data are normalized to levels found in adeno-GFP-infected
neurons that were set at 1 (dashed line). Results are Mean 6 s.d. (n=3
independent cultures; *P,0.05; **P,0.01). (C) e18.5 WT or p532/2
neurons were infected with adenoviruses and analyzed for ROS levels as
in (A). Data were expressed as fold change relative to levels in Adeno-
GFP-infected WT neurons. Results are Mean 6 s.d. (n=3 independent
cultures; *P,0.05).
doi:10.1371/journal.pone.0031870.g005
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the mutant sample. Scale bars; 50 mm.
(TIF)
Figure S2 Cultured WT and Bmi1
2/2 neurons were
infected or not with an adenovirus expressing a
dominant-negative form of p53, and gene expression
levels were analyzed by qPCR 48 hours later. P53
inhibition restored IL-6 expression, but not p16
Ink4a and p19
Arf
expression, to levels comparable to those found in WT neurons.
Data are normalized to hprt expression levels. Results are Mean
+/2 s.d. (n=4 independent cultures; **P,0.01 when compared
to Bmi12/2).
(TIF)
Information S1 Contains the description of supplemen-
tary methods.
(DOC)
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